CLINICAL PROGNOSTIC FACTORS IN SURGICALLY TREATED STAGE IIIA-N2 NONSMALL CELL LUNG-CANCER - ANALYSIS OF THE LITERATURE

Citation
Jf. Vansteenkiste et al., CLINICAL PROGNOSTIC FACTORS IN SURGICALLY TREATED STAGE IIIA-N2 NONSMALL CELL LUNG-CANCER - ANALYSIS OF THE LITERATURE, Lung cancer, 19(1), 1998, pp. 3-13
Citations number
45
Categorie Soggetti
Oncology,"Respiratory System
Journal title
ISSN journal
01695002
Volume
19
Issue
1
Year of publication
1998
Pages
3 - 13
Database
ISI
SICI code
0169-5002(1998)19:1<3:CPFIST>2.0.ZU;2-Y
Abstract
There remains controversy on the prognostic value of several common cl inical factors in NSCLC patients with resected N2-disease. The aim of this paper is to give a comprehensive overview of the available data o n this issue. Literature data on surgically treated N2-NSCLC-patients from 1980-1995, peer reviewed and listed in Index Medicus, were analys ed. Reported and calculated or estimated survival data were indexed. E ighteen series were selected: in 12 of them, direct comparisons betwee n survival curves of subgroups are reported; six contained sufficient data to make comparisons of survivors at 5 years; three of them also m ade a multivariate Cox model. The analysis of prognostic factors in a single study was often hampered by the limited number of patients. Non etheless, it could be concluded that patients with a clinical N0- or N 1-status (so-called unforeseen N2) do better. There was no clear diffe rence between patients undergoing lobectomy or pneumonectomy. There wa s strong evidence that N2-patients with a less advanced primary tumour (T-stage) have a better prognosis, and this is the case for all opera ble T-stages (T1 versus T2, T1 versus T3, T2 versus T3). Squamous cell type was a favourable prognostic factor, as was the presence of only one metastatic mediastinal lymph node station or absence of metastases to the subcarinal nodes. There was some evidence that the presence of extracapsular spread in metastatic MLN is an unfavourable finding. St ratification for these prognostic factors could help in the planning o f future trials on combined modality treatment in N2-NSCLC. (C) 1998 E lsevier Science Ireland Ltd.